Semaglutide

What Is Semaglutide?

Semaglutide is a synthetic version of a hormone the body naturally produces called GLP-1, short for glucagon-like peptide-1. GLP-1 is released from the gut after eating and plays a role in regulating blood sugar and signaling fullness to the brain.^[1] Semaglutide is built to mimic that hormone's activity while lasting far longer in the body than natural GLP-1, which normally breaks down within minutes.

Unlike most of the compounds covered on this site, semaglutide isn't a research-only peptide. It's an FDA-approved medication with one of the largest human clinical trial programs of any drug in its class, spanning both diabetes management and weight management indications.

What Semaglutide Is Being Researched For

• Blood Sugar Control

  Semaglutide's original approval was for type 2 diabetes, based on its ability to lower blood sugar by increasing insulin release and reducing glucagon, a hormone that raises blood sugar.^[1]

• Body Weight

  A large body of clinical trial data, most notably the STEP trial program, has examined semaglutide's effect on body weight in people with overweight or obesity.^[2]

• Cardiovascular Outcomes

  A large-scale trial in people with cardiovascular disease and overweight or obesity, but without diabetes, found that semaglutide reduced the rate of major cardiovascular events compared to placebo over roughly three years of follow-up.^[3]

How Semaglutide Works

• Mimicking GLP-1 Signaling

  Research points to semaglutide binding to the same receptor as the body's natural GLP-1 hormone, which triggers increased insulin release and reduced glucagon release in response to food, helping regulate blood sugar after meals.^[1]

• Slowing Digestion and Signaling Fullness

  Research points to semaglutide slowing how quickly food moves through the stomach and acting on appetite-regulating areas of the brain, which together are tied to reduced food intake in clinical trials.^[2]

• Lasting Longer in the Body

  Research points to structural modifications in semaglutide that allow it to resist the enzymes that break down natural GLP-1 within minutes, extending its activity to about a week and enabling once-weekly dosing.^[1]

Reconstitution and Handling

Semaglutide is available in FDA-approved pre-filled pen formulations, but research-grade vials sold as lyophilized powder are also common and require reconstitution with bacteriostatic water before use. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Semaglutide stands apart from most compounds covered on this site because it's an FDA-approved medication with an unusually large and well-documented human clinical trial base, spanning diabetes, weight management, and cardiovascular outcomes. Its core mechanism centers on mimicking the body's natural GLP-1 hormone while resisting rapid breakdown, extending its activity from minutes to roughly a week. Research continues to expand into areas beyond its original approvals.

Frequently Asked Questions

Sources and Research

1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.